Healthcare
Celcuity Inc.(CELC)
Live Price
Offline$88.55
-1.05% today
1Y Change
+644.64%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $6.85B
- Revenue Growth
- 0.0%
- EPS Growth
- -33.6%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Celcuity Inc. (CELC) is a Healthcare stock with a market cap of $6.85B and listed on NASDAQ. The stock last traded around $88.55 and up 644.6% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -33.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -33.6%, free cash flow -83.4% with operating margin 0.0% and ROIC -40.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CELC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -33.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +8.2% | +12.8% | -28.1% |
2026 Mar 25, 2026 | +8.5% | +4.2% | +2.5% | +3.0% |
2025 Nov 12, 2025 | +9.8% | +1.0% | +10.7% | +18.3% |
Benchmark Edge
CELC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CELC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CELC Max Drawdown
-39.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CELC and SPY.
Company Overview
Celcuity Inc.
NASDAQ
Celcuity Inc. is a clinical-stage biotechnology company focused on advancing oncology therapeutics and precision cancer diagnostics. The company develops innovative approaches to cancer treatment through its lead therapeutic candidate, gedatolisib, a potent pan-PI3K and mTOR inhibitor currently being evaluated in the VIKTORIA-1 Phase 3 clinical trial for patients with HR+/HER2- advanced breast cancer. Beyond therapeutics, Celcuity operates the CELx diagnostic platform, a proprietary technology that analyzes patients' living tumor cells to identify the specific cellular abnormalities driving their cancer and determine the most effective targeted therapies. This dual approach combines drug development with companion diagnostics to improve clinical outcomes for cancer patients. The platform enables physicians to match patients with appropriate targeted treatments based on individual tumor biology. Founded in 2012 and headquartered in Minneapolis, Minnesota, Celcuity bridges the gap between therapeutic innovation and personalized medicine in oncology.
- Leadership
- Mr. Brian F. Sullivan
- Employees
- 155
- Street Address
- 16305 36th Avenue North, Suite 100
- Mailing
- Minneapolis, MN, 55446
- Region
- Minneapolis, MN, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 74.0
Growth
- Revenue
- 0.0%
- EPS
- -33.6%
- Free Cash Flow
- -83.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -203.2%
- ROIC
- -40.8%
Balance Sheet
- Debt/Equity
- 1.94
- Current Ratio
- 10.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.